Financials Giant Biogene Holding Co., Ltd.

Equities

2367

KYG3887G1091

Personal Products

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
52.55 ^HKD	-0.66%		+8.24%	+47.61%

Apr. 30	Giant Biogene’s Profit Up 47% in 2023	MT
Mar. 26	Giant Biogene to Pay Special 0.45 Yuan per Share Dividend	MT

Valuation

Fiscal Period: December	2022	2023	2024	2025	2026
Capitalization ¹	28,963	31,581	47,427	-	-
Enterprise Value (EV) ²	27,686	29,210	43,392	41,922	40,137
P/E ratio	30 x	22.2 x	26.8 x	21.1 x	17.2 x
Yield	-	1.34%	1.08%	1.38%	1.69%
Capitalization / Revenue	12.2 x	8.96 x	10.1 x	7.88 x	6.3 x
EV / Revenue	11.7 x	8.29 x	9.26 x	6.97 x	5.33 x
EV / EBITDA	23.8 x	17.8 x	21 x	16.3 x	12.8 x
EV / FCF	35.5 x	-	30.7 x	22.3 x	17.2 x
FCF Yield	2.81%	-	3.26%	4.49%	5.82%
Price to Book	10.7 x	-	8.72 x	6.75 x	5.34 x
Nbr of stocks (in thousands)	976,000	976,000	976,000	-	-
Reference price ³	33.60	35.60	52.55	52.55	52.55
Announcement Date	3/27/23	3/25/24	-	-	-

¹HKD in Million²CNY in Million³HKD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2022	2023	2024	2025	2026
Net sales ¹	2,364	3,524	4,688	6,018	7,523
EBITDA ¹	1,161	1,645	2,062	2,571	3,126
EBIT ¹	1,134	1,611	2,026	2,592	3,238
Operating Margin	47.95%	45.71%	43.21%	43.07%	43.04%
Earnings before Tax (EBT) ¹	1,178	1,745	2,117	2,693	3,337
Net income ¹	1,002	1,452	1,798	2,275	2,806
Net margin	42.38%	41.19%	38.36%	37.8%	37.3%
EPS ²	1.120	1.605	1.964	2.487	3.062
Free Cash Flow ¹	779	-	1,415	1,884	2,336
FCF margin	32.95%	-	30.18%	31.3%	31.05%
FCF Conversion (EBITDA)	67.1%	-	68.61%	73.29%	74.72%
FCF Conversion (Net income)	77.74%	-	78.68%	82.81%	83.25%
Dividend per Share ²	-	0.4772	0.5678	0.7255	0.8890
Announcement Date	3/27/23	3/25/24	-	-	-

¹CNY in Million²HKD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2022 S2	2023 S1	2023 S2	2024 S1	2024 S2
Net sales ¹	1,641	1,606	1,918	2,199	2,582
EBITDA	-	-	-	-	-
EBIT ¹	771.9	714.3	896.7	900.6	1,057
Operating Margin	47.03%	44.49%	46.74%	40.95%	40.95%
Earnings before Tax (EBT)	-	-	969.5	-	-
Net income	-	-	784.8	-	-
Net margin	-	-	40.91%	-	-
EPS	-	-	-	-	-
Dividend per Share	-	-	-	-	-
Announcement Date	3/27/23	8/28/23	3/25/24	-	-

¹CNY in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-
Net Cash position ¹	1,276	2,371	4,034	5,505	7,289
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow ¹	779	-	1,415	1,884	2,336
ROE (net income / shareholders' equity)	54.9%	40.8%	34.7%	33.7%	32.3%
ROA (Net income/ Total Assets)	19.2%	36.2%	31%	30.7%	30.7%
Assets ¹	5,225	4,009	5,800	7,411	9,137
Book Value Per Share ²	3.150	-	6.030	7.790	9.840
Cash Flow per Share ²	1.030	-	2.300	3.010	3.980
Capex ¹	153	-	193	166	178
Capex / Sales	6.46%	-	4.13%	2.75%	2.36%
Announcement Date	3/27/23	3/25/24	-	-	-

¹CNY in Million²HKD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Giant Biogene Holding Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

52.55 HKD

Average target price

54.76 HKD

Spread / Average Target

+4.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Personal Products

	1st Jan change	Capi.
GIANT BIOGENE HOLDING CO., LTD.	+47.61%	6.56B
PROCTER & GAMBLE COMPANY	+13.86%	394B
UNILEVER PLC	+12.84%	134B
COLGATE-PALMOLIVE COMPANY	+19.31%	78.02B
HINDUSTAN UNILEVER LIMITED	-11.50%	66.3B
ESTEE LAUDER	-9.74%	47.33B
KENVUE INC.	-4.60%	39.33B
ESSITY AB	+11.64%	18.09B
GODREJ CONSUMER PRODUCTS LIMITED	+16.77%	16.17B
DABUR INDIA LIMITED	-1.15%	11.68B

Other Personal Products